Predictive Value of the Chinese Visceral Adiposity Index for Metabolic Dysfunction-Associated Fatty Liver Disease and Elevated Alanine Aminotransferase Levels in Nonobese Chinese Adults: A Cross-Sectional Study
Zuohu Niu,Jialiang Chen,Huijing Wang,Rongrui Wang,Hongye Peng,Shaojie Duan,Shukun Yao
DOI: https://doi.org/10.2147/jir.s468093
IF: 4.5
2024-06-19
Journal of Inflammation Research
Abstract:Zuohu Niu, 1, &ast Jialiang Chen, 2, &ast Huijing Wang, 3, &ast Rongrui Wang, 3, 4 Hongye Peng, 3 Shaojie Duan, 5 Shukun Yao 4 1 Department of Infections, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, People's Republic of China; 2 Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China; 3 Graduate School, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 4 Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, People's Republic of China; 5 Department of Geriatrics, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shaojie Duan, Department of Geriatrics, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, People's Republic of China, Email Shukun Yao, Department of Gastroenterology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, 100029, People's Republic of China, Email Purpose: It is unclear how the Chinese Visceral Adiposity Index (cVAI) relates to metabolic dysfunction-associated fatty liver disease (MAFLD) and alanine aminotransferase (ALT) in nonobese individuals. In this study, we evaluated the ability of the cVAI to predict MAFLD and elevated ALT in nonobese participants. Methods: This cross-sectional study recruited 541 nonobese subjects from March 2019 to January 2022 with the age range of 18– 80 years. Hepatic steatosis was diagnosed by ultrasound. Participants were divided into four groups according to cVAI quartiles. To assess the associations between cVAI and MAFLD and elevated ALT, multivariate logistic regression was used. Receiver operating characteristic (ROC) curves were generated to evaluate the ability of the cVAI to predict MAFLD and elevated ALT. Results: Compared to the group with the lowest cVAI, the group with the highest cVAI was positively associated with nonobese MAFLD [16.173 (4.082– 64.073), P < 0.001] and elevated ALT [8.463 (2.859– 25.049), P 38 and ≤ 38 years old subgroups ( P < 0.05), respectively. In addition, the ability of the cVAI to predict MAFLD was better in females, young individuals, and individuals with a higher education level ( P < 0.05). The cVAI also had good predictive ability for elevated ALT levels [0.655 (0.602– 0.708)], particularly in females, young people, and highly educated participants. Furthermore, the cVAI was strongly positively correlated with the liver fibrosis score ( P < 0.05) and was also a strong indicator of concomitant metabolic syndrome in nonobese MAFLD patients [AUC = 0.688 (0.612– 0.763)]. Conclusion: The cVAI was strongly related to nonobese MAFLD and elevated ALT. The cVAI may be a reliable and accessible predictor of nonobese MAFLD and elevated ALT. Keywords: Chinese visceral adiposity index, metabolic dysfunction-associated fatty liver disease, nonobese, Chinese, cross-sectional study In 2020, the term metabolic dysfunction-associated fatty liver disease (MAFLD) was used in place of nonalcoholic fatty liver disease (NAFLD). 1,2 MAFLD has superior utility in identifying patients at high risk for metabolic dysfunction and hepatic and extrahepatic complications, 3 and the definition has now been promoted globally. 4 The prevalence of MAFLD has increased over the past decade due to lifestyle changes and ambient air pollution. 5 Globally, MAFLD has been identified as the major cause of chronic liver disease, especially within China, where it currently accounts for thirty percent of cases. 6 The prevalence of MAFLD increases with age, and patients are predominantly male. 7 Without intervention, MAFLD can progress to steatohepatitis, hepatic fibrosis, and ultimately liver tumors. 1,2,8 Furthermore, MAFLD represents a multisystem disease that is strongly related to cancer, chronic kidney disease, and cardiovascular disease. 8,9 Given that metabolic syndrome (MS) is the key factor underlying MAFLD, it is reasonable to infer that other diseases closely associated with MS are also related to MAFLD. 10 MAFLD has emerged as an enormous financial burden and is now an increasing worldwide health issue. Liver biopsy is the most accurate met -Abstract Truncated-
immunology